A Safety and Efficacy Study for Treatment of Painful Vertebral Compression Fractures Caused by Osteoporosis
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Doctors are studying an investigational treatment to be used during the vertebroplasty procedure when treating vertebral compression fractures (spine fractures) that may help to reduce pain and restore mobility. If one has experienced back pain for at least 4 weeks but not longer than 1 year, he/she may be eligible to participate.
The purpose of this protocol is to describe the methods for the clinical evaluation of Cortoss for vertebroplasty in patients with painful osteoporotic compression fractures.
Eligible patients with painful osteoporotic compression fractures of the spine are divided into two groups. Each enrolled patient will have the vertebroplasty procedure; however one group of patients will have the vertebroplasty procedure using polymethylmethacrylate [PMMA] (a Food and Drug Administration [FDA]-approved bone cement) and the other group of patients will have the vertebroplasty procedure using a relatively new (investigational) biomaterial called Cortoss.
| Condition | Intervention |
|---|---|
|
Spinal Fractures |
Device: Percutaneous Vertebral Augmentation of compression fractures |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | A Randomized, Controlled Clinical Study to Evaluate the Safety and Effectiveness of CORTOSS® Synthetic Cortical Bone Void Filler in Vertebral Augmentation |
- Early and sustained decrease in pain (efficacy prong of primary endpoint) at 24 months compared to pre-treatment baseline using the Visual Analog Scale (VAS) [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- Maintenance or improvement in function (efficacy prong of primary endpoint) at 24 months compared to pre-treatment baseline using the Oswestry Disability Index (ODI) [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- Maintenance vertebral height and alignment (efficacy prong of primary endpoint) at 24 Months compared to 1-month post-vertebropalsty baseline radiographs [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- No device-related subsequent surgical intervention at study treated level [ Time Frame: 24 Months ] [ Designated as safety issue: Yes ]
- Maintenance or improvement in quality of life (secondary endpoint) at 24 months compared to baseline using the SF-12 [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- Ambulatory status [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- Patient satisfaction [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
| Enrollment: | 256 |
| Study Start Date: | September 2004 |
| Estimated Study Completion Date: | March 2009 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: CORTOSS
Patients prospectively randomized to be treated with Cortoss constitute treatment group.
|
Device: Percutaneous Vertebral Augmentation of compression fractures
Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
Other Names:
|
|
Active Comparator: PMMA
Patients prospectively randomized to be treated with PMMA constitute active control group.
|
Device: Percutaneous Vertebral Augmentation of compression fractures
Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
Other Names:
|
Detailed Description:
This is a prospective, multi-center randomized, controlled study designed to evaluate the safety and effectiveness of Cortoss® Synthetic Cortical Bone Void Filler in vertebral augmentation using the percutaneous vertebroplasty technique. Study eligible patients with painful osteoporotic compression fractures will be randomized (2:1) to vertebroplasty with Cortoss (treatment group) or PMMA (control group), respectively. Patients will not be told which treatment they will receive (single blind study design). Safety and effectiveness will be determined by comparing the success rate of the treatment group to the success rate of the control group. Secondary endpoints will include Quality of Life, Patient satisfaction, evaluation of the patient's pain and function post-operatively compared to baseline, and maintenance of vertebral body height and alignment.
For the purposes of this study, vertebral augmentation, or vertebroplasty, is defined as a minimally invasive procedure utilizing manual instruments and radiological guidance to deliver an in-situ polymerizable material to stabilize a collapsed or fractured vertebral body. The goal is to alleviate pain caused by the fracture and enhance or prevent further deterioration of function.
This multi-center study will evaluate Cortoss for the augmentation of one or two vertebra(e), fractured as a result of osteoporosis, located between (and including) the levels of the sixth thoracic and the fifth lumbar vertebrae. A total of 243 patients will be enrolled at up to 19 sites. All subjects must have radiographic evidence of a vertebral body fracture due to osteoporosis. After complying with all eligibility criteria, subjects will sign an informed consent document and will be randomized into vertebroplasty treatment with Cortoss or PMMA (1:1 ratio). Patients will be followed for at least 24 months and recruitment is expected to take between 9 and 12 months. Visits and assessments are planned according to the time and events schedule.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Are at least 18 years of age
- Have sustained a painful osteoporotic vertebral compression fracture (VCF) for at least 4 weeks but no longer than 1 year or have radiographic evidence of at least 5% worsening vertebral collapse as compared to previous radiographic evidence
- Give written Informed Consent to participate in the study and be willing to comply with protocol requirements
- Have pain requiring the regular use of analgesics or have a substantially altered life-style due to pain or disability
- Have central pain over the spinous process upon palpation at the planned level(s)
- Are appropriately communicative to verbalize and differentiate with regard to location and intensity of their pain
- Are physically and mentally willing and able to comply with the clinical and radiographic follow-up schedule
- Have radiographic evidence of one or two, Grade 1 or greater according to Genant's criteria, osteoporotic VCF(s) between (and including) the level of the sixth (6th) thoracic to the fifth (5th) lumbar
- Have an acute or persistent (not healed) fracture demonstrated by magnetic resonance imaging (MRI) or bone scan
- Have a patient self-assessment VAS score >= 50 mm at the pre-treatment visit
- Have a 30% or greater disability score on the baseline ODI (version 2.0).
Exclusion Criteria:
- Have significant vertebral collapse defined as more than 70% of original vertebral height, or a burst or pedicle fracture with posterior cortical wall disruption
- Have posterior vertebral wall displacement occupying more than 20% of the cross sectional area of the spinal canal
- Have neurologic symptoms or deficits, or radiculopathy related to the VCF
- Have pain based on a clinical diagnosis of herniated nucleus pulposus, high energy trauma, severe spinal stenosis as evidenced by progressive weakness or paralysis, or bone tumor at the level(s) of pathology as evidenced by computed tomography (CT) scan
- Have indications of instability related to the VCF at the level to be treated (e.g., neurologic deficit, kyphosis > 30º, translation > 4 mm, and/or interspinous process widening)
- Have canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level(s) to be treated
- Have a bleeding disorder, including coagulopathy
- Have severe cardiopulmonary deficiencies
- Have an active systemic or local infection
- Are currently being treated for cancer or HIV
- Have a known allergy to acrylics (e.g., methyl methacrylate)
- Subject is currently an alcohol, solvent or drug abuser
- Female patients who are pregnant or nursing, or of childbearing potential not using a reliable contraceptive method
- Are involved in medical litigation
- Are prisoners
- Have participated in another investigational study within 30 days prior to inclusion
Contacts and Locations| United States, Arizona | |
| Scottsdale Medical Center | |
| Scottsdale, Arizona, United States, 85251 | |
| United States, California | |
| Core Orthopaedic Medical Center, P.C. | |
| Encinitas, California, United States, 92024 | |
| Eisenhower Medical Center | |
| Rancho Mirage, California, United States, 92270 | |
| St. John's Spine Institute | |
| Santa Monica, California, United States, 90404 | |
| United States, Florida | |
| Indian River Radiology | |
| Vero Beach, Florida, United States, 32960 | |
| United States, Georgia | |
| Emory Orthopaedics and Spine Center | |
| Atlanta, Georgia, United States, 30329 | |
| United States, Illinois | |
| Millenium Pain Center | |
| Bloomington, Illinois, United States, 61701 | |
| Northwestern University | |
| Chicago, Illinois, United States, 60611 | |
| United States, Louisiana | |
| The Spine Institute of Louisiana | |
| Shreveport, Louisiana, United States, 71101 | |
| United States, Missouri | |
| Washington University Medical Center | |
| St. Louis, Missouri, United States, 63110 | |
| United States, New York | |
| Montefiore Medical Center | |
| Bronx, New York, United States, 10467 | |
| Hospital for Special Surgery (HSS) | |
| New York, New York, United States, 10021 | |
| United States, North Carolina | |
| Mission Hospitals | |
| Asheville, North Carolina, United States, 28801 | |
| United States, Ohio | |
| Dayton Interventional Radiology | |
| Kettering, Ohio, United States, 45409 | |
| United States, Oklahoma | |
| Edmond Medical Center | |
| Oklahoma City, Oklahoma, United States, 73034 | |
| Mercy Health Center | |
| Oklahoma City, Oklahoma, United States, 73120 | |
| United States, Pennsylvania | |
| Pennsylvania Hospital | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| United States, Texas | |
| Endovascular Center of Houston | |
| Houston, Texas, United States, 77030 | |
| Study Director: | Maarten Persenaire, M.D. | Orthovita, Inc. |
More Information
Additional Information:
No publications provided
| Responsible Party: | Maarten Persenaire, M.D., Chief Medical Officer, Orthovita |
| ClinicalTrials.gov Identifier: | NCT00290862 History of Changes |
| Other Study ID Numbers: | 1100-0008 |
| Study First Received: | February 10, 2006 |
| Last Updated: | October 13, 2008 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Orthovita:
|
Osteoporosis Spine fracture Back Pain Vertebroplasty Vertebral compression fractures related to osteoporosis |
Additional relevant MeSH terms:
|
Fractures, Bone Osteoporosis Spinal Fractures Fractures, Compression Wounds and Injuries Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Spinal Injuries |
Back Injuries Polymethyl Methacrylate Vasodilator Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Antimutagenic Agents Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 22, 2013